This Psychedelics Stock Could Grow 300% In One Year
Cantor Fitzgerald initiated coverage of Cybin (NYSE: CYBN), a drug development company in the psychedelics sector.
Analysts gave Cybin an overweight rating and a 12-month price target of $9. Cybin shares were $2.25 at the time of this writing.
